In summary, targeting the NLRP3 inflammasome is a viable strategy for inhibiting pyroptosis and treating respiratory diseases, whereas other targets, such as caspase-1, also exhibit therapeutic potential. This evidence concerns the gene CASP1 and respiratory system disorder.